BMO Reaffirms Eli Lilly and Company (LLY) as an Obesity Market Leader [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
an ‘Outperform' rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,200. Matching the consensus 1-year median target price, the stock has an upside potential of 16.36%. The firm remains confident in the company's solid leadership position in the obesity treatment space and beyond for 2026 and the years ahead. BMO Capital pointed out that growth and certainty for the company's incretin business is backed by broadening access, the expected launch of orforglipron, and the company's growing portfolio. While maintaining its leadership in the obesity market, Eli Lilly and Company (NYSE:LLY) also has a solid presence in other disease areas, particularly Lp(a), which contributes to its long-term growth outlook, the firm added. Pixabay/Public Domain Two days earlier, Eli Lilly and Company (NYSE:LLY) announced a partnership with NVIDIA to develop an AI co-innovation lab focused on pharmaceutical research. The leading entities plan to invest up to $1 billion in talent, inf
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancerPR Newswire
- Smaller portions, more protein: How GLP-1s are quietly changing chain restaurant menus [MSNBC.com]MSNBC.com
- Prediction: 2026 Will Be the Year of Eli Lilly [Yahoo! Finance]Yahoo! Finance
- What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative [Yahoo! Finance]Yahoo! Finance
- Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026? [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 1/8/26 - Form 4
- 1/6/26 - Form 3
- 1/6/26 - Form 4
- LLY's page on the SEC website